- In April 2023, F. Hoffmann-La Roche Ltd. (Switzerland), a global leader in oncology diagnostics, announced the launch of an integrated diagnostic platform in South Africa to support early detection of lung cancer. The initiative aimed to expand access to molecular and imaging diagnostics in underserved regions, underscoring Roche’s commitment to improving cancer outcomes through advanced technology and global outreach
- In March 2023, Guardant Health, Inc. (U.S.) launched an updated version of its Guardant360® CDx liquid biopsy test specifically designed for detecting actionable mutations in non-small cell lung cancer (NSCLC) patients. The new assay version gained FDA approval as a companion diagnostic for multiple targeted therapies, reinforcing Guardant Health’s leadership in non-invasive cancer diagnostics
- In March 2023, Thermo Fisher Scientific Inc. successfully expanded its portfolio of lung cancer companion diagnostics by launching an NGS-based assay compatible with multiple platforms. This assay, designed for use in oncology reference labs, enables comprehensive genomic profiling of tumor samples to guide precision therapy for NSCLC patients
- In February 2023, Qiagen N.V. (Germany) partnered with several diagnostic laboratories across Asia-Pacific to introduce its QIAstat-Dx syndromic testing platform, which includes panels for detecting genetic mutations related to lung cancer. This strategic collaboration enhances Qiagen's footprint in the fast-growing APAC diagnostics market and aims to accelerate personalized treatment strategies
- In January 2023, Illumina, Inc. and Myriad Genetics, Inc. announced a strategic partnership to co-develop lung cancer-specific genomic testing workflows. The initiative focuses on simplifying NGS adoption in community hospitals and clinics by offering bundled solutions for both sequencing and data interpretation, driving broader access to lung cancer genomic profiling
